Hoffman-La Roche is developping a new MC4 agonist for the treatment of ED, similar to Palatin's bremelanotide. There's very little information on this, but it shows that centrally acting ED drugs really do have a future.

You can read the trial information here:

Study Posting (4519) Trial #103542, Erectile Dysfunction, Piscataway, NJ